Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis

References

• Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023 Feb;11(2):e197–e206. doi: 10.1016/S2214-109X(22)00501-0
   PubMed Web of Science ®Google Scholar
• Alfaro K, Maza M, Cremer M, et al. Removing global barriers to cervical cancer prevention and moving towards elimination. Nat Rev Cancer. 2021 Oct;21(10):607–608. doi: 10.1038/s41568-021-00396-4
   PubMed Web of Science ®Google Scholar
• Senkomago V, Henley SJ, Thomas CC, et al. Human papillomavirus-attributable cancers - United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724–728. doi: 10.15585/mmwr.mm6833a3
   PubMed Web of Science ®Google Scholar
• Melkonian SC, Henley SJ, Senkomago V, et al. Cancers associated with human papillomavirus in American Indian and Alaska native populations - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1283–1287. doi: 10.15585/mmwr.mm6937a2
   PubMed Web of Science ®Google Scholar
• Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020 Feb;122(3):306–314. doi: 10.1038/s41416-019-0602-7
   PubMed Web of Science ®Google Scholar
• Perkins RB, Wentzensen N, Guido RS, et al. Cervical cancer screening: a review. JAMA. 2023 Aug 8;330(6):547–558. doi: 10.1001/jama.2023.13174
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048–1056. doi: 10.1016/S1470-2045(10)70230-8
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303–315. doi: 10.1093/jnci/djj067
   PubMed Web of Science ®Google Scholar
• Harper DM, Jimbo M. Elimination of cervical cancer depends on HPV vaccination and primary HPV screening. Lancet Infect Dis. 2021 Oct;21(10):1342–1344. doi: 10.1016/S1473-3099(20)30992-0
   PubMed Web of Science ®Google Scholar
• Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer. Vaccines (Basel). 2021 Nov 30;9(12):1413. doi: 10.3390/vaccines9121413
   PubMed Web of Science ®Google Scholar
• Huang R, Gan R, Zhang D, et al. The comparative safety of human papillomavirus vaccines: a bayesian network meta-analysis. J Med Virol. 2022 Feb;94(2):729–736. doi: 10.1002/jmv.27304
   PubMed Web of Science ®Google Scholar
• Goldstone SE, Giuliano AR, Palefsky JM, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022 Mar;22(3):413–425. doi: 10.1016/S1473-3099(21)00327-3
   PubMed Web of Science ®Google Scholar
• Joura EA, Ulied A, Vandermeulen C, et al. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: an open-label phase 3 study. Vaccine. 2021 May 12;39(20):2800–2809. doi: 10.1016/j.vaccine.2021.01.074
   PubMed Web of Science ®Google Scholar
• Li M, Zhao C, Zhao Y, et al. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: data from China. Front Immunol. 2023;14:1112750. doi: 10.3389/fimmu.2023.1112750
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Oct;12(10):781–789. doi: 10.1016/S1473-3099(12)70187-1
   PubMed Web of Science ®Google Scholar
• Mariz FC, Gray P, Bender N, et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Lancet Infect Dis. 2021 Oct;21(10):1458–1468. doi: 10.1016/S1473-3099(20)30873-2
   PubMed Web of Science ®Google Scholar
• Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991–998. doi: 10.1016/S0140-6736(05)67069-9
   PubMed Web of Science ®Google Scholar
• Cornell JE. The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses. Ann Intern Med. 2015 Jun 2;162(11):797–798. doi: 10.7326/M15-0930
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021 Mar 29;10(1):89. doi: 10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–560. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011 Feb;64(2):163–171. doi: 10.1016/j.jclinepi.2010.03.016
   PubMed Web of Science ®Google Scholar
• White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012 Jun;3(2):111–125. doi: 10.1002/jrsm.1045
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017 Nov 11;390(10108):2143–2159. doi: 10.1016/S0140-6736(17)31821-4
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711–723. doi: 10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010 Mar 3;102(5):325–339. doi:10.1093/jnci/djp534
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009 Apr 1;199(7):926–935. doi: 10.1086/597307
   PubMed Web of Science ®Google Scholar
• Zhao FH, Wu T, Hu YM, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1756–1768. doi: 10.1016/S1473-3099(22)00435-2
   PubMed Web of Science ®Google Scholar
• Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145–153. doi: 10.1093/jnci/djz074
   PubMedGoogle Scholar
• Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014 Dec 1;135(11):2612–2622. doi: 10.1002/ijc.28897
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017 Jan;6(1):12–25. doi: 10.1002/cam4.869
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 Oct;8(14):6195–6211. doi: 10.1002/cam4.2399
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014 Sep 3;32(39):5087–5097. doi: 10.1016/j.vaccine.2014.06.038
   PubMed Web of Science ®Google Scholar
• Herrero R, Wacholder S, Rodríguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011 Oct;1(5):408–419. doi: 10.1158/2159-8290.CD-11-0131
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr 15;367(9518):1247–1255. doi: 10.1016/S0140-6736(06)68439-0
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009 Dec 12;374(9706):1975–1985. doi: 10.1016/S0140-6736(09)61567-1
   PubMed Web of Science ®Google Scholar
• Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer. 2010 Apr;20(3):404–410. doi: 10.1111/IGC.0b013e3181d373a5
   PubMed Web of Science ®Google Scholar
• Konno R, Yoshikawa H, Okutani M, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother. 2014;10(7):1781–1794. doi: 10.4161/hv.28712
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan;13(1):100–110. doi: 10.1016/S1470-2045(11)70287-X
   PubMed Web of Science ®Google Scholar
• Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015 Apr;22(4):361–373. doi: 10.1128/CVI.00591-14
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan;13(1):89–99. doi: 10.1016/S1470-2045(11)70286-8
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014 Dec 20;384(9961):2213–2227. doi: 10.1016/S0140-6736(14)60920-X
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016 Oct;16(10):1154–1168. doi: 10.1016/S1473-3099(16)30120-7
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011 Dec;7(12):1343–1358. doi: 10.4161/hv.7.12.18281
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;5(5):Cd009069. doi: 10.1002/14651858.CD009069.pub3
   PubMedGoogle Scholar
• Karimi-Zarchi M, Allahqoli L, Nehmati A, et al. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. BMC Public Health. 2020 Feb 27;20(1):274. doi: 10.1186/s12889-020-8371-z
   PubMed Web of Science ®Google Scholar
• Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013 Aug;130(2):264–268. doi: 10.1016/j.ygyno.2013.04.050
   PubMed Web of Science ®Google Scholar
• Di Tucci C, Schiavi MC, Faiano P, et al. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. Crit Rev Oncol Hematol. 2018 Aug;128:30–42. doi: 10.1016/j.critrevonc.2018.05.011
   PubMed Web of Science ®Google Scholar
• Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010 Oct 27;8(1):105. doi: 10.1186/1479-5876-8-105
   PubMedGoogle Scholar
• de Villiers, EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004 Jun 20;324(1):17–27. doi: 10.1016/j.virol.2004.03.033
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011 Dec;7(12):1359–1373. doi: 10.4161/hv.7.12.18282
   PubMed Web of Science ®Google Scholar
• Bowden SJ, Doulgeraki T, Bouras E, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023 Jul 27;21(1):274. doi: 10.1186/s12916-023-02965-w
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cai X, Shen F, et al. HPV post-infection microenvironment and cervical cancer. Cancer Lett. 2021 Jan 28;497:243–254. doi: 10.1016/j.canlet.2020.10.034
   PubMed Web of Science ®Google Scholar
• Bogani G, Sopracordevole F, Ciavattini A, et al. Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023 Nov 1;32(6):525–532. doi: 10.1097/CEJ.0000000000000822
   PubMed Web of Science ®Google Scholar
• Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18–25. doi: 10.1016/j.ygyno.2008.06.027
   PubMed Web of Science ®Google Scholar
• Akhatova A, Azizan A, Atageldiyeva K, et al. Prophylactic human papillomavirus vaccination: from the origin to the Current state. Vaccines (Basel). 2022 Nov 11;10(11):1912. doi: 10.3390/vaccines10111912
   PubMed Web of Science ®Google Scholar
• Llave CL, MEV U, Lam HY, et al. The cost-effectiveness of human papillomavirus vaccination in the Philippines. Vaccine. 2022 Jun 15;40(27):3802–3811. doi:10.1016/j.vaccine.2022.05.025
   PubMed Web of Science ®Google Scholar
• Zou Z, Fairley CK, Ong JJ, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020 Oct;8(10):e1335–e1344. doi: 10.1016/S2214-109X(20)30277-1
   PubMed Web of Science ®Google Scholar